Topics

Astellas, Adaptimmune To Co-Develop And Co-Commercialize T-cell Therapies

03:34 EST 14 Jan 2020 | FinanzNachrichten

TOKYO (dpa-AFX) - Tokyo, Japan-based Astellas Pharma Inc. (ALPMY) announced Tuesday an agreement with Adaptimmune Therapeutics plc (ADAP), which is focused on cell therapy to treat cancer, to deve...

Original Article: Astellas, Adaptimmune To Co-Develop And Co-Commercialize T-cell Therapies

NEXT ARTICLE

More From BioPortfolio on "Astellas, Adaptimmune To Co-Develop And Co-Commercialize T-cell Therapies"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...